Paper Details

  1. Home
  2. Paper Details

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial.

Author: AlkanSerhan, BartonKevin, GermanoEliza, GodwinJohn, MichaelisLaura, NandSucha, RychlikKaren, SmithScott, StiffPatrick, VeerappanRanjitha

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This Phase II study assessed the efficacy and toxicity of a combination regimen of hydroxyurea (HU), azacitidine, and low-dose gemtuzumab ozogamicin (GO) in elderly patients with AML and high-risk MDS. The regimen achieved a CR in 70% of patients, with a median remission duration of 8 months and median survival of 10 months. Overall toxicity was manageable.
Paper Details　
Original Abstract of the Article :
Elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) have a poor prognosis due to low response rates (26-46%) to standard chemotherapy and high treatment-related mortality (11-31%). In this Phase II study, we used a combination of hydroxyurea (HU), azaciti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/10428190802451254

データ提供：米国国立医学図書館（NLM）

A Novel Treatment Approach for Elderly AML and MDS: A New Oasis in the Desert

Acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) are serious hematologic malignancies, particularly challenging for elderly patients. This research explores a novel treatment regimen for elderly patients with AML and MDS, combining hydroxyurea (HU), azacitidine, and low-dose gemtuzumab ozogamicin (GO). This approach is like a multi-pronged attack on a formidable desert fortress, aiming to overcome the challenges of treating these complex diseases in older adults.

A Promising Regimen: Improved Outcomes

The study found that this regimen demonstrated promising results, achieving a high complete response rate (70%) and acceptable toxicity. It’s like discovering a hidden spring in the desert, offering a new source of hope and potentially leading to improved outcomes for elderly patients.

A Glimmer of Hope: Further Research Needed

The research provides a valuable starting point for future investigations into the efficacy of this regimen in a larger cohort of patients. It’s like a journey through a vast desert, requiring ongoing research to further refine and optimize this promising treatment approach.

Dr.Camel's Conclusion

This research explores a novel treatment approach for elderly patients with AML and MDS, offering a glimmer of hope in the desert of hematologic malignancies. The study’s promising results warrant further investigation to confirm the efficacy and safety of this regimen in a larger population.

Date :
  1. Date Completed 2009-01-07
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

19021057

DOI: Digital Object Identifier

10.1080/10428190802451254

Related Literature

Article Analysis
・Side Effects of azacitidine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.